I've been reviewing the EMA's guidelines document that PAR mention in reference to a TGA provisional application.
Something they seem big on is JSN, Joint space narrowing, specifically as measured by X-Ray.
PAR mention as the only segment they review by x-ray.
They don't however directly attribute any of the results to Joint space width or narrowing, there's mention of MRI a lot but not of X-Ray results.
I'm assuming where they're talking about improvements in cartilage loss, this is perhaps analogous to JSN?
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-162
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |